Lapatinib and Bevacizumab for Metastatic Breast Cancer

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT00444535
Phase
PHASE2
Status
Completed

Conditions

  • Neoplasms, Breast

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib — DRUG
    1500 mg oral lapatinib (once daily)
  • bevacizumab — DRUG
    10 mg/kg intravenous bevacizumab (every two weeks)

Study Details

This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.

Key Dates

Start date
Feb 27, 2007
Status verified
Sep 2021
Primary completion
Jul 22, 2008
Completion
Jun 19, 2020

Study Design

Enrollment
52 participants (actual)
Allocation
NA
Primary purpose
TREATMENT

Arms

  • Experimental: Oral lapatinib tablets in combination with IV bevacizumab
    1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)

Primary Outcome Measure

Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment [ Time Frame: up to week 12 ]

Locations (9)

FacilityCityStateZIPSite coordinators
Novartis Investigative SiteTucsonArizona85724-
Novartis Investigative SiteSan FranciscoCalifornia94115-
Novartis Investigative SiteHollywoodFlorida33021-
Novartis Investigative SiteTampaFlorida33612-
Novartis Investigative SiteBasking RidgeNew York07920-
Novartis Investigative SiteCommackNew York11725-
Novartis Investigative SiteNew YorkNew York10065-
Novartis Investigative SiteRockville CentreNew York11570-
Novartis Investigative SiteSleepy HollowNew York10591-

Find similar trials in Tucson, AZ

By research site
Novartis Investigative Site· Tucson, AZNovartis Investigative Site· San Francisco, CANovartis Investigative Site· Hollywood, FLNovartis Investigative Site· Tampa, FLNovartis Investigative Site· Basking Ridge, NYNovartis Investigative Site· Commack, NY